9 As is the case of other OM devices, data from a multi‐institutional controlled clinical trial were lacking.
Some model studies support pGDT cost-effectiveness, but real economic data based on a recent clinical trial are lacking.
A few models are available for the evaluation of GDT cost-effectiveness, but studies of real economic data based on a recent clinical trial are lacking.
In a recent Swiss observational study [ 16], it was suggested that a drug with a different mechanism of action, such as rituximab, has greater potential benefit in this setting, but a corroborating randomized trial is lacking.
One recent scientific review concluded that there was some evidence suggesting it could have a role, but the gold standard of proof necessary for confirmation and further evaluation – randomised clinical trials – were lacking.
However, human trials are lacking.
However, data from randomized trials are lacking.
A variety of endoscopic techniques have been proposed, but controlled prospective trials are lacking.
Determining the benefits of a screening test is complex, particularly when information from randomized trials is lacking.
N-of-1 trials are a unique trial design which can inform personalized evidence-based decisions for the patient when data from traditional clinical trials are lacking or not generalizable.
